As shown in Figure 3E, the result indicated that SCL treatment at dosages of 200 and 400 mg/kg markedly decreased the serum level of VEGF (p < 0.05, p < 0.01), suggesting that SCL could repress angiogenesis in the H22 transplanted tumor. The gene discussed is VEGFA; the disease is neoplasm.